Ushbu ishga iqtibos qilgan ishlar

2 ta ish

Ish: Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3)

1. Catumaxomab

   James E. Frampton

   Sharh maqolaNanoparticle-Based Drug DeliveryDrugs20121 iqtibos

   ABIABI:AkademIndex/openalex/2012.review-article.000001

2. Catumaxomab: First Approval

   Yahiya Y. Syed

   Sharh maqolaCancer therapeutics and mechanismsDrugs20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.review-article.000255